albumin binding is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
固体状态的 tirzepatide 通常以冻干粉形式保存，推荐在低温、避光、干燥条件下存放，常见区间为 2 至 8 摄氏度，长期保存可考虑更低温度并避免反复冻融。冻融循环会导致肽链聚集或析出，从而影响后续定量结果。容器密封性与湿度控制同样是稳定性研究中反复强调的因素。
溶解操作一般使用注射用水或适宜的水性缓冲液，必要时加入少量助溶剂以改善溶解速度，但应避免剧烈涡旋振荡，因为剪切力可能促进聚集。配制后的溶液在冷藏条件下的稳定时间通常短于固体形态，具体时限取决于浓度、缓冲体系与容器材质。是否加入防腐成分，则取决于用途是否为多次取样。
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
| Property | Value | Notes |
|---|---|---|
| 储存温度 | 2 至 8 摄氏度 | 固体粉末，避光密封 |
| 外观 | 白色至类白色冻干粉 | 溶解后为澄清至微乳光 |
| 溶解性 | 易溶于水性缓冲液 | 避免剧烈振荡 |
| 常规纯度方法 | 反相高效液相色谱 | 紫外或质谱检测 |
| 定量方法 | 液相色谱串联质谱 | 配合固相萃取前处理 |
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Identity and purity are established with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion verifies the primary sequence and detects substitutions. Size-exclusion chromatography quantifies aggregates and fragments, which are the impurities most often tracked for peptides of this size. Residual solvents, counterions, and water content fall under separate tests described in pharmacopeial chapters. Circular dichroism or nuclear magnetic resonance may be used in research settings to probe secondary structure, though such methods are less common in routine release testing.
Peptide active ingredients of this type are typically supplied as lyophilized powder because the dry form resists hydrolysis during transport. The material is hygroscopic, so vials are usually equilibrated to room temperature before opening to avoid condensation on the solid. Repeated freeze-thaw cycles can promote aggregation and are generally avoided by aliquoting stock into single-use portions. Personnel handling the powder work in controlled environments to limit inhalation of fine particles. Written procedures usually specify these steps rather than leaving them to individual judgment.
Pharmacologically, tirzepatide activates two distinct G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Binding at each target triggers cyclic AMP accumulation and downstream signaling in pancreatic beta cells, adipose tissue and the central nervous system. Because the two pathways overlap only partially, the combined effect on insulin secretion, glucagon suppression and appetite signaling differs from that of selective single-receptor compounds. Affinity is not equal across the two targets, and the clinical meaning of that imbalance remains an area of active study.
Clinical research programs have evaluated tirzepatide in adults with type 2 diabetes and in adults with obesity or excess weight. Trials generally reported reductions in glycated hemoglobin and body weight across treatment periods of several months. Since these studies enrolled defined populations under controlled conditions, the findings describe group averages rather than individual outcomes. Open questions include the durability of effects after treatment stops, variation among subgroups, and the long-term consequences of sustained dual receptor stimulation. Published trial summaries should be consulted for exact measurements rather than secondary accounts.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
Artifacts found outside their original context (ex situ), often due to natural disturbances or amateur excavations, have less interpretive value, but may provide clues about the spatial distribution and typological characteristics of unexcavated in situ deposits, guiding future excavation efforts. The Convention on the Protection of the Underwater Cultural Heritage sets mandatory guidelines for signatory states regarding the treatment of underwater shipwrecks. One of its main principles is that in situ preservation is the preferred approach. This policy is based on the unique conditions of underwater environments, where low oxygen levels and stable temperatures help preserve artifacts over long periods. Removing artifacts from these conditions and exposing them to the atmosphere often accelerates deterioration, particularly the oxidation of iron-based materials. In mortuary archaeology, in situ documentation involves systematically recording and cataloging human remains in their original depositional positions. These remains are often embedded in complex matrices of sediment, clothing, and associated artifacts. Excavating mass graves presents additional challenges, as they may contain hundreds of individuals. Before identifying individuals or determining causes of death, archaeologists must carefully document spatial relationships and contextual details to preserve forensic and historical information.
=== 1.2a === DisplayPort version 1.2a was released in January 2013 and may optionally include VESA's Adaptive Sync. AMD's FreeSync uses the DisplayPort Adaptive-Sync feature for operation. FreeSync was first demonstrated at CES 2014 on a Toshiba Satellite laptop by making use of the Panel-Self-Refresh (PSR) feature from the Embedded DisplayPort standard, and after a proposal from AMD, VESA later adapted the Panel-Self-Refresh feature for use in standalone displays and added it as an optional feature of the main DisplayPort standard under the name "Adaptive-Sync" in version 1.2a. As it is an optional feature, support for Adaptive-Sync is not required for a display to be DisplayPort 1.2a-compliant.
== Climate == The climate of Stanley is classified as a subpolar oceanic climate (Köppen Cfc), bordering very closely on a polar climate (ET). Nowadays it barely avoids classification as ET because the mean temperature is greater than 10 °C (50 °F) for two months of the year. Unlike typical tundra climates, however, the winters are very mild, and vegetation grows there that normally could not in a climate this close to a polar climate. Contrast this with Churchill, Manitoba, which also has a near-tundra climate but is much more continental in nature. The Falkland Islands have displayed a warming trend in recent years; the mean daily January maximum for Mount Pleasant for the years 1999-2012 is 15.1 °C (59.2 °F) compared to Stanley's 1961-90 average of 14.1 °C (57.4 °F). Formerly, Stanley had a tundra climate (ET), due to cool summer temperatures (the mean temperature was less than 10 °C or 50 °F in the hottest month). Like the rest of the archipelago, Stanley has more or less even temperatures through the year and strong westerlies. Precipitation, averaging 544 mm (21.42 in) a year, is nonetheless relatively low, and evenly spread throughout the year. Typically, at least 1 mm (0.039 in) of rain will be recorded on 125.2 days of the year. The islands receive 36.3% of possible sunshine, or around 1500–1600 hours a year, a level similar to southern parts of England. Daytime temperatures are similar to the Northern Isles of Scotland, though nights tend to be somewhat colder, with frost occurring on more than 1 in 3 nights (128.4 nights). Snow occurs in the winter.
== Causes == The cause of pattern hair loss is not yet fully understood. It appears to be the result of genetic changes that make the activity of hair follicles on the scalp become sensitive to the presence of androgenic hormones, cholesterol, and proteins such as insulin-like growth factor.
=== EC 1.1.99 With unknown physiological acceptors === EC 1.1.99.1: choline dehydrogenase EC 1.1.99.2: L-2-hydroxyglutarate dehydrogenase EC 1.1.99.3: gluconate 2-dehydrogenase (acceptor) EC 1.1.99.4: dehydrogluconate dehydrogenase EC 1.1.99.5: now EC 1.1.5.3, glycerol-3-phosphate dehydrogenase EC 1.1.99.6: D-2-hydroxy-acid dehydrogenase EC 1.1.99.7: lactate—malate transhydrogenase EC 1.1.99.8: Now EC 1.1.2.7, methanol dehydrogenase (cytochrome c) and EC 1.1.2.8, alcohol dehydrogenase (cytochrome c).
Sources: en.wikipedia.org
Medical conditions that can cause joint hypermobility include FASDs, Stickler syndrome, Ehlers–Danlos syndrome, Marfan syndrome, Loeys–Dietz syndrome, rheumatoid arthritis, osteogenesis imperfecta, lupus, polio, Fragile X syndrome, Down syndrome, Morquio syndrome, cleidocranial dysostosis and myotonia congenita. All have other diagnostic criteria as well. Current thinking suggests four causative factors:
Creatine methyl ester is the methyl ester derivative of the amino acid creatine. It can be prepared by the esterification of creatine with methanol. By undergoing an esterification process with methanol, this compound seeks to enhance creatine's absorption rate in the body. Creatine esters, like creatine methyl ester, have been studied for their potential to improve bioavailability when compared to standard creatine monohydrate.
Responding to Curzon in January 1919, Balfour wrote "Weizmann has never put forward a claim for the Jewish Government of Palestine. Such a claim in my opinion is clearly inadmissible and personally I do not think we should go further than the original declaration which I made to Lord Rothschild". In February 1919, France issued a statement that it would not oppose putting Palestine under British trusteeship and the formation of a Jewish State. Friedman further notes that France's attitude went on to change; Yehuda Blum, while discussing France's "unfriendly attitude towards the Jewish national movement", notes the content of a report made by Robert Vansittart (a leading member of the British delegation to the Paris Peace Conference) to Curzon in November 1920 which said:
=== Other forms of melanins === Up until the 1960s, melanin was classified into eumelanin and pheomelanin. However, in 1955, a melanin associated with nerve cells was discovered, neuromelanin. In 1972 a water-soluble form, pyomelanin, was discovered, derived from the oxidation of homogentisic acid. In 1976, allomelanin, the fifth form of the melanins, was found in nature. It is derived from the oxidation of compounds such as 1,8-dihydroxynaphthalene, 1,4,6,7,9,12-hexahydroxyperylene-3,10-quinone, and catechol.
Sources: en.wikipedia.org
=== Laboratory methods === In the laboratory, glycerol reacts with oxalic or formic acids to give (respectively) dioxalin or glyceric formate, either of which decarboxylate and dehydrate to allylol. Allyl alcohols in general are prepared by allylic oxidation of allyl compounds, using selenium dioxide or organic peroxides. Other methods include carbon-carbon bond-forming reactions such as the Prins reaction, the Morita-Baylis-Hillman reaction, or a variant of the Ramberg-Bäcklund reaction. Hydrogenation of enones is another route. Some of these methods are achieved by the Luche reduction, Wharton reaction, and the Mislow-Evans rearrangement. Allyl alcohol was first prepared in 1856 by Auguste Cahours and August Hofmann by hydrolysis of allyl iodide. Allyl alcohol can be formed by trituration of garlic (Allium sativum) cloves (producing from garlic in two ways: firstly by a self-condensation reaction of allicin and its decomposition products such as diallyl trisulphide and diallyl disulphide and secondly by the reaction between alliin, the precursor of allicin, and water). The compound's various connections with garlic give the allyl group its name (from Latin "allium" meaning garlic).
The brand name featured on the label is usually the same as the distillery name (for example, the Talisker distillery labels its whiskies with the Talisker name). Indeed, the SWR prohibits bottlers from using a distillery name when the whisky was not made there. A bottler's name may also be listed, sometimes independent of the distillery. In addition to requiring that Scotch whisky be distilled in Scotland, the SWR requires that it also be bottled and labelled in Scotland. Labels may also indicate the region of the distillery (for example, Islay or Speyside). Alcoholic strength is expressed on the label by Alcohol By Volume (ABV) or sometimes simply "Vol". Typically, bottled whisky is between 40% and 46% ABV. Whisky is considerably stronger when first emerging from the cask—normally 60–63% ABV. Water is then added to create the desired bottling strength. If the whisky is not diluted before bottling, it can be labelled as cask strength. A whisky's age may be listed on the bottle providing a guarantee of the youngest whisky used. An age statement on the bottle, in the form of a number, must reflect the age of the youngest whisky used to produce that product. A whisky with an age statement is known as guaranteed age whisky. Scotch whisky without an age statement may, by law, be as young as three years old. In the early 21st century, such "No age statement" whiskies have become more common, as distilleries respond to the depletion of aged stocks caused by improved sales. A label may carry a distillation date or a bottling date.
== Mechanism of action == Didanosine (ddI) is a nucleoside analogue of adenosine. It differs from other nucleoside analogues, because it does not have any of the regular bases, instead it has hypoxanthine attached to the sugar ring. Within the cell, ddI is phosphorylated to the active metabolite of dideoxyadenosine triphosphate, ddATP, by cellular enzymes. Like other anti-HIV nucleoside analogs, it acts as a chain terminator by incorporation and inhibits viral reverse transcriptase by competing with natural dATP.
=== ATLAS and P-body === ATLAS and P-body (known as Blue and Orange to GLaDOS) are player characters in the co-op campaign of Portal 2. They are two robots that cannot speak and can only produce grunts, which are voiced by Dee Bradley Baker. They are equipped with their own portal guns which bears the colour of its user (blue and purple for ATLAS, yellow and red for P-body). Atlas and P-Body are described as masculine and feminine, respectively, as stated by Chet Faliszek in an interview. During the campaign, GLaDOS calls them Blue and Orange, respectively, and constantly tries to ruin their relationship by awarding one and ignoring the other. GLaDOS sends ATLAS and P-body into four areas to access data discs. Once done, they are blown up, as GLaDOS claims it is the only way they can be retrieved from these areas. Later, GLaDOS commands them to retrieve a certain "surprise" in an area. They go in search, only to find hundreds of thousands of other test subjects in suspended animation. After the co-op campaign is finished, GLaDOS quotes that they saved science. ATLAS and P-body begin to celebrate, only to be promptly blown up by GLaDOS. In the DLC campaign "Peer Review", ATLAS and P-body are reactivated by GLaDOS one week after the original co-op campaign, during which GLaDOS has already wiped out all of the found test subjects in her attempts to turn them into "killing machines". The two robots are sent to find a saboteur that has taken control of a prototype central core and is causing problems in the facility.
== Research == SGLT2 inhibitors increase circulating ketone body concentrations. The cardioprotective effects of SGLT2 inhibitors have been attributed to the elevated ketone levels. Gliflozins have been posited to exhibit protective effects on the heart, liver, kidneys, anti‐hyperlipidemic, anti‐atherosclerotic, anti‐obesity, anti‐neoplastic effects in in vitro, pre‐clinical, and clinical studies. Pleiotropic effects of this class have been attributed to a variety of its pharmacodynamic actions such as natriuresis, hemoconcentration, deactivation of renin–angiotensin–aldosterone system, ketone body formation, alterations in energy homeostasis, glycosuria, lipolysis, anti‐inflammatory, and antioxidative actions. SGLT2 inhibitors have shown beneficial effects on liver function in clinical trials on individuals with NAFLD and type 2 diabetes, and also on those without type 2 diabetes. SGLT2 inhibitors also modified the adverse effects of ozone in heart failure, indicating a potential cardioprotective role. SGLT2 inhibitors have anti-inflammatory and immunomodulatory effects through pathways such as NF-κB, AMPK/mTOR, and JAK/STAT.
Sources: en.wikipedia.org
建议在低温、避光、干燥环境中密封保存，常见条件为 2 至 8 摄氏度，长期存放可置于更低温度。应避免反复冻融，并尽量减少容器开启次数。
溶解后的稳定时间通常短于固体形态，受浓度、缓冲液和容器材质影响。冷藏条件下一般只能维持较短时间，具体期限应通过实际稳定性实验确认。
反相高效液相色谱用于纯度与含量测定，液相色谱串联质谱用于生物基质中的定量，体积排阻色谱用于检测聚集体。多种方法结合才能较完整地表征样品。
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.